Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Department of Cognitive Neurology, Institute for Neurological Research Fleni, Buenos Aires, Argentina.
Alzheimers Dement. 2021 Apr;17(4):653-664. doi: 10.1002/alz.12227. Epub 2020 Nov 23.
A growing number of dominantly inherited Alzheimer's disease (DIAD) cases have become known in Latin American (LatAm) in recent years. However, questions regarding mutation distribution and frequency by country remain open.
A literature review was completed aimed to provide estimates for DIAD pathogenic variants in the LatAm population. The search strategies were established using a combination of standardized terms for DIAD and LatAm.
Twenty-four DIAD pathogenic variants have been reported in LatAm countries. Our combined dataset included 3583 individuals at risk; countries with highest DIAD frequencies were Colombia (n = 1905), Puerto Rico (n = 672), and Mexico (n = 463), usually attributable to founder effects. We found relatively few reports with extensive documentation on biomarker profiles and disease progression.
Future DIAD studies will be required in LatAm, albeit with a more systematic approach to include fluid biomarker and imaging studies. Regional efforts are under way to extend the DIAD observational studies and clinical trials to Latin America.
近年来,越来越多的常染色体显性遗传阿尔茨海默病(DIAD)病例在拉丁美洲(LatAm)被发现。然而,关于各国突变分布和频率的问题仍未得到解答。
我们完成了一项文献综述,旨在为拉丁美洲人群中的 DIAD 致病性变异提供估计。使用 DIAD 和 LatAm 的标准化术语组合来建立搜索策略。
在拉丁美洲国家已经报告了 24 种 DIAD 致病性变异。我们的综合数据集包括 3583 名高危个体;DIAD 发病率最高的国家是哥伦比亚(n=1905)、波多黎各(n=672)和墨西哥(n=463),通常归因于创始人效应。我们发现相对较少的报告有关于生物标志物特征和疾病进展的广泛记录。
拉丁美洲需要开展未来的 DIAD 研究,尽管需要更系统的方法来纳入液体生物标志物和成像研究。区域努力正在进行中,以将 DIAD 观察性研究和临床试验扩展到拉丁美洲。